Santhera Pharmaceuticals Holding AG

As of December 31, 2025, Santhera Pharmaceuticals Holding AG carries a market capitalization of 183.53M, placing it among publicly traded companies globally. Its enterprise value stands at 212.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Santhera Pharmaceuticals Holding AG's next confirmed earnings release is scheduled for April 29, 2027.

As of December 31, 2025, Santhera Pharmaceuticals Holding AG has 13.39M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Santhera Pharmaceuticals Holding AG maintains a current ratio of 1.29, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Santhera Pharmaceuticals Holding AG's stock has gained approximately 43.82% over the past 52 weeks. The 50-day moving average sits at 16.37, while the 200-day moving average is 16.77.

As of December 31, 2025, Santhera Pharmaceuticals Holding AG holds 24.10M in cash and equivalents against 52.58M in total debt, resulting in a net debt position of 26.37M. Total book value stands at -12.69M, with working capital of 19.41M providing operational flexibility.

Santhera Pharmaceuticals Holding AG's most recent stock split took place on July 3, 2023 with a 10:1 split ratio.